Company intelligence / Profile preview
Bioflag
Jiangsu, Chinaen.bioflag.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Bioflag has commercialized multiple proprietary probiotic strains with clinical validation for gut health, metabolic benefits including weight management and body fat reduction, immune support in infants and adults; products are used in infant formula and dietary supplements across Asia-Pacific and exported globally.
- Therapeutic areas
- Metabolic DisordersPsychiatryGastroenterologyEndocrinologyOtherImmunology
- Modalities
- Live biotherapeutic product therapyProbioticPostbiotic
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Aunulife/Ausnutria for infant nutrition productsvarious global supplement brands using their ingredients
Beyond the preview
Go deeper on Bioflag.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioflag.